Literature DB >> 27543619

Presurgical Biomarker Performance in the Detection of Gleason Upgrading in Prostate Cancer.

Kristina Wittig1, Johnathan L Yamzon1, David D Smith2, Daniel R Jeske2,3, Steven S Smith4,5.   

Abstract

BACKGROUND: Gleason Score (GS) upgrading is generally considered a trigger for exit to definitive treatment during active surveillance (AS). Predicting the potential for GS upgrading would be of value in assessing AS eligibility.
METHODS: We assessed the performance of biomarkers in presurgical specimens of expressed prostatic secretion (EPS) in this setting.
RESULTS: Although EPS volume, total recovered RNA, and RNA expression biomarkers (TMPRSS2: ERG, PCA3, PSA) have been successful in both biopsy outcome prediction, and in the prediction of upstaging in active surveillance eligible patients, they were unable to predict upgrading in patients eligible for active surveillance under National Comprehensive Cancer Network guidelines.
CONCLUSIONS: These biomarkers do not improve the prediction of upgrading over indications from standard clinical parameters. IMPACT: Additional biomarkers will be needed in this area. Cancer Epidemiol Biomarkers Prev; 25(12); 1643-5. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27543619      PMCID： PMC5704940          DOI： 10.1158/1055-9965.EPI-16-0488

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN： 1055-9965            Impact factor:   4.254


  6 in total

1.  Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA.

Authors:  Scott A Tomlins; Sheila M J Aubin; Javed Siddiqui; Robert J Lonigro; Laurie Sefton-Miller; Siobhan Miick; Sarah Williamsen; Petrea Hodge; Jessica Meinke; Amy Blase; Yvonne Penabella; John R Day; Radhika Varambally; Bo Han; David Wood; Lei Wang; Martin G Sanda; Mark A Rubin; Daniel R Rhodes; Brent Hollenbeck; Kyoko Sakamoto; Jonathan L Silberstein; Yves Fradet; James B Amberson; Stephanie Meyers; Nallasivam Palanisamy; Harry Rittenhouse; John T Wei; Jack Groskopf; Arul M Chinnaiyan
Journal:  Sci Transl Med       Date:  2011-08-03       Impact factor: 17.956

2.  Underestimation of Gleason score at prostate biopsy reflects sampling error in lower volume tumours.

Authors:  Niall M Corcoran; Chris M Hovens; Matthew K H Hong; John Pedersen; Rowan G Casey; Stephen Connolly; Justin Peters; Laurence Harewood; Martin E Gleave; S Larry Goldenberg; Anthony J Costello
Journal:  BJU Int       Date:  2011-09-02       Impact factor: 5.588

3.  The Gleason score shift: score four and seven years ago.

Authors:  Derek B Chism; Alexandra L Hanlon; Patricia Troncoso; Tahseen Al-Saleem; Eric M Horwitz; Alan Pollack
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-08-01       Impact factor: 7.038

4.  Performance of a single assay for both type III and type VI TMPRSS2:ERG fusions in noninvasive prediction of prostate biopsy outcome.

Authors:  Jarrod P Clark; Kristofer W Munson; Jessie W Gu; Katarzyna Lamparska-Kupsik; Kevin G Chan; Jeffrey S Yoshida; Mark H Kawachi; Laura E Crocitto; Timothy G Wilson; Ziding Feng; Steven S Smith
Journal:  Clin Chem       Date:  2008-10-23       Impact factor: 8.327

5.  Expressed prostatic secretion biomarkers improve stratification of NCCN active surveillance candidates: performance of secretion capacity and TMPRSS2:ERG models.

Authors:  Christopher Whelan; Mark Kawachi; David D Smith; Jennifer Linehan; Gail Babilonia; Rosa Mejia; Timothy Wilson; Steven S Smith
Journal:  J Urol       Date:  2013-05-10       Impact factor: 7.450

6.  A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer.

Authors:  Bharathi Laxman; David S Morris; Jianjun Yu; Javed Siddiqui; Jie Cao; Rohit Mehra; Robert J Lonigro; Alex Tsodikov; John T Wei; Scott A Tomlins; Arul M Chinnaiyan
Journal:  Cancer Res       Date:  2008-02-01       Impact factor: 12.701
  6 in total
  1 in total

1.  Prevalence and clinical application of TMPRSS2-ERG fusion in Asian prostate cancer patients: a large-sample study in Chinese people and a systematic review.

Authors:  De-Pei Kong; Rui Chen; Chun-Lei Zhang; Wei Zhang; Guang-An Xiao; Fu-Bo Wang; Na Ta; Xu Gao; Ying-Hao Sun
Journal:  Asian J Androl       Date:  2020 Mar-Apr       Impact factor: 3.285
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.